Two Vanderbilt researchers among 200 earning “Best Invention of 2022” from TIME magazine
Monoclonal antibodies and early stroke detection landed these Vanderbilt researchers in TIME Magazine.
Two Vanderbilt University faculty members who conducted translational research in totally different fields have received the distinction of earning “Best Invention of 2022” from TIME magazine. They were among 200 researchers honored by the publication.
- James Crowe Jr., Director of the Vaccine Center at Vanderbilt University Medical Center, led the team that discovered a monoclonal antibody combination that protects against COVID-19. Optimized and developed by AstraZeneca, the monoclonal antibody combination called Evusheld is the first treatment to protect adults and children 12 years and older who have compromised immune systems before exposure to the virus.
- James Weimer, Assistant Professor of Computer Science and faculty affiliate of the Vanderbilt Institute for Surgery and Engineering, is the researcher behind Neuralert, a lightweight, noninvasive wristband device that automates stroke detection and alerting. One of the hallmark indicators of stroke is asymmetrical arm movement, which is displayed as weakness, neglect or less movement on one side. Neuralert’s stroke detection device can identify the onset of asymmetric movement in as little as 15 minutes, even if the wearer is asleep.
“These winning innovations exemplify the transformative potential of university research when it aims to solve society’s most urgent problems, and when universities partner with the broader innovation ecosystem to bring new solutions to market faster,” Vanderbilt Chancellor Daniel Diermeier said. “I congratulate Dr. Crowe and Professor Weimer and their teams on these life-saving, landmark accomplishments.”
Click here to learn more about their work.
